Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravenous Recombinant Human Prourokinase for Extended-Window Acute Ischemic Stroke Selected by NCCT-Based Artificial Intelligence: A Randomized Controlled Trial

NCT07901842 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.

NCT NCT07901842 Not yet recruiting Phase 3 826 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07901842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started December 2026. Interventional study, Phase 3, 826 participants (estimated). Lead sponsor Second Affiliated Hospital, Zhejiang University, School of Medicine; China. Primary measure: Proportion of Participants With a Modified Rankin Scale Score of 0-1 at 90 Days.

How it compares

263 similar trials: same condition (Ischemic Stroke) and phase

Enrollment

This trial
826
Middle half
222 to 991
Median
520
Trials with a value
263

Months from start to completion

This trial
42
Middle half
22 to 45.2
Median
29.6
Trials with a value
256

Sites

This trial
1
Middle half
1 to 22
Median
1
Trials with a value
241
Posted results or a linked paper 56% 148 of 263 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
Intravenous Recombinant Human Prourokinase for Extended-Window Acute Ischemic Stroke Selected by NCCT-Based Artificial Intelligence: A Randomized Controlled Trial
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
June 1, 2030
Enrollment
826 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Ischemic Stroke

Registry terms: acute ischemic stroke

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
China
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
Recombinant Human Prourokinase Group Experimental Recombinant Human Prourokinase for Injection (rhPro-UK)
Show registry wording

Participants will receive intravenous recombinant human prourokinase (rhPro-UK), 35 mg, in addition to guideline-recommended standard stroke care.

Matching Placebo Group Placebo comparator Matching Placebo for Recombinant Human Prourokinase
Show registry wording

Participants will receive matching intravenous placebo in addition to the same guideline-recommended standard stroke care.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Proportion of Participants With a Modified Rankin Scale Score of 0-1 at 90 Days 90 ± 7 days after randomization
Show registry wording

The proportion of participants achieving a modified Rankin Scale (mRS) score of 0 or 1. The mRS ranges from 0 (no symptoms) to 6 (death), with lower scores indicating better functional outcomes.

Lead sponsor's other trials

Second Affiliated Hospital, Zhejiang University, School of Medicine, most recent start first.

Similar trials

Same condition (Ischemic Stroke) and phase, most recent start first.